Clinical Trial

Ultralow Dose PET Imaging of 18F-flurpiridaz

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for known or suspected coronary artery disease (for detecting myocardial ischemia or infarction) detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-flurpiridaz and be imaged on a new type of high sensitivity PET scanner for up to 3 hours
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-08.
Status change: Not Yet Recruiting → Enrolling by Invitation 2026-04-07
Trial Details
NCT Number NCT07284576
Lead Sponsor Akiva Mintz
Conditions Healthy Volunteer, Coronary Arterial Disease, Myocardial Ischemia, Myocardial Infarction
Enrollment 200 participants
Start Date 2025-12-16
Primary Completion 2030-06-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-13